Lv7
3470 积分 2021-12-14 加入
Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non–Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B)
8天前
已完结
【需要补充材料SI 感谢！】First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations
14天前
已完结
First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations
14天前
已完结
Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial
1个月前
已完结
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
2个月前
已完结
One Pivotal Trial, the New Default Option for FDA Approval — Ending the Two-Trial Dogma
3个月前
已完结
Efficacy and safety of MRG002 monotherapy in treating patients with locally advanced or metastatic breast cancer with low HER2 expression: A multi-center, non-randomized, open-label phase II clinical trial
5个月前
已完结
Overall Survival with Inavolisib in PIK3CA -Mutated Advanced Breast Cancer
5个月前
已完结
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
5个月前
已完结
Lepodisiran — A Long-Duration Small Interfering RNA Targeting Lipoprotein(a)
6个月前
已完结
皖公网安备34019202002308
